Search

Your search keyword '"RiboTargets Ltd. -- Contracts"' showing total 3 results
Start Over Descriptor "RiboTargets Ltd. -- Contracts"
3 results on '"RiboTargets Ltd. -- Contracts"'

1. Postitive news for marimastat; British Biotech's drug shows promise against nonoperable gastric cancer

Author

Fox, Sophia

Subjects
British Biotech PLC -- Product development, Scotia Holdings PLC -- Product development, Novartis AG -- Research, Imutran PLC -- Research, Cambridge Antibody Technology Group PLC -- Research, LeukoSite Inc. -- Contracts, Ilex Oncology Inc. -- Contracts, Bayer HealthCare Pharmaceuticals -- Contracts, Glaxo Wellcome PLC -- Product discontinuation, Wyeth -- Mergers, acquisitions and divestments, Stagecoach Group PLC -- Investigations, Cyclacel Ltd. -- Finance, Bayer AG -- Product introduction, BioFocus PLC -- Contracts, Roche Holding Ltd. -- Contracts, Warner-Lambert Co. Parke-Davis Pharmaceutical Research Div. -- Contracts, RiboTargets Ltd. -- Contracts, Tepnel Life Sciences -- Mergers, acquisitions and divestments, Nuclyx -- Mergers, acquisitions and divestments, Pharmagene Inc. -- Finance, British Linen Bank Ltd. -- Finance, Kleinwort Benson Group PLC -- Finance, Sanofi-Synthelabo -- Product introduction, Bavarian Nordic Research Institute A/S -- Product development, Oxford Molecular Group PLC -- Product development, Cambridge Antibody Technology Group PLC -- Product development, Pharmaceutical industry, Biological products industry, Biotechnology industry, Business, European Union
Abstract

This is a roundup of news about European Union's biotechnology industry. It includes the promising trial result of Marimastat, British Biotech PLC's anticancer drug for gastric cancer treatment. Other news includes marketing agreement for new drugs, and research and development in genetic engineering and biological products.

Published
1999

2. RiboTargets licenses 1st compound

Subjects
Ribotargets Ltd. -- Contracts, Ribotargets Ltd. -- Licensing agreements, Analgesics -- Contracts, Analgesics -- Licensing agreements, Company licensing agreement, Business, Pharmaceuticals and cosmetics industries, University of Monash -- Contracts, University of Monash -- Licensing agreements
Abstract

RiboTargets has licensed the alphadone pain treatment from two scientists at Australia's University of Monash. The neurosteroid drug is in preclinical/Phase 1 stage.

Published
2002

3. MOLECULAR SIMULATIONS INC

Subjects
Ribotargets Ltd. -- Contracts, Molecular Simulations Inc. -- Contracts, Software, Computer software industry -- Contracts, Drugs, Pharmaceutical industry -- Contracts, Software quality, Contract agreement, Business, Chemicals, plastics and rubber industries
Abstract

MOLECULAR SIMULATIONS Inc. (MSI) and RiboTargets Ltd. have begun a three-year strategic collaboration to develop software specific to both modeling of RNA targets and the design of RNA-targeted drugs. RiboTarget, [...]

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results